Activation of the TLR5/MyD88/NME3/NFκB signaling pathway enhances host immunity, enhances the clearance of tumor xenografts, and potentially augments the effectiveness of immunotherapy, prolonging survival in breast cancer patients (91). This evidence concerns the gene MYD88 and breast carcinoma.